Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain
Conget, Ignacio (Hospital Clínic i Provincial de Barcelona)
Mauricio Puente, Dídac (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Ortega Basagoiti, Rafael (GlaxoSmithKline)
Detournay, Bruno (Cemka Eval)

Data:	2016
Resum:	Several glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) have been made recently available in Spain for type 2 diabetes mellitus (DM2) treatment. There are no published data on the clinical and sociodemographic profile of patients initiating treatment with GLP-1Ra in Spain. Our objective was to understand these patients' characteristics in a real-world clinical practice setting. Design. Cross-sectional observational study. Setting. Spanish specialist outpatient clinics. Participants 403 adults with DM2 initiating GLP-1Ra treatment were included. Primary and secondary outcome measures Sociodemographic and DM2-related clinical data, including treatment at and after GLP-1Ra initiation and comorbidities, were collected. Results Evaluable patients (n=403; 50. 9% female) were included (July 2013 to March 2014) at 24 centres by 53 specialists (47 endocrinology, 6 internal medicine), with the following profile (value±SD): age (58. 3±10. 4 years), diabetes duration (9. 9±7 years), body mass index (BMI; 36. 2±5. 5) and glycated haemoglobin (HbA1c; 8. 4±1. 4%); 14% had HbA1c≤7%. Previous antidiabetic treatment: 53. 8% only oral antidiabetic drugs (OADs), 5. 2% insulin and 40% insulin and OAD; of those receiving OAD, 35% single drug, 38. 2% 2 drugs and 24% 3 drugs. Concomitant to GLP-1Ra, 55. 3% were only on OAD, 36. 2% on insulin and OAD, and 7. 2% only on insulin. Of those receiving OAD, the GLP-1Ra was mainly associated with 1 drug (65%) or 2 drugs (31. 8%). GLP-1Ra are frequently added to existing antidiabetic drugs, with dipeptidyl peptidase-4 inhibitors being the OAD most frequently switched (45% receiving 1 before starting GLP-1Ra, only 2. 7% receiving it concomitantly). Conclusions In Spain, GLP-1Ra therapy is usually started in combination with OADs or OADs and insulin. These drugs are used in relatively young patients often not reaching therapeutic goals with other treatment combinations, roughly a decade after diagnosis and with a relatively high BMI. The latter could be explained by Spanish regional payers limiting reimbursed prescription to patients with a minimum BMI threshold (>30 in most regions, >35 in some).
Nota:	Ajuda rebuda: GlaxoSmithKline
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Diabetis ; Insulina ; Diabetes mellitus tipo 2 ; Diabetis mellitus tipus 2 ; DM2
Publicat a:	BMJ open, Vol. 6 Núm. 7 (July 2016) , p. e010197, ISSN 2044-6055

DOI: 10.1136/bmjopen-2015-010197
PMID: 27466235

Article 8 p, 898.4 KB

Correcció 2 p, 314.0 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats